Recent Company News

• 10:27 AM ET Jul 10, 2026
  

  Follow-up: FDA approves Keytruda and Keytruda QLEX, each with Padcev, for muscle invasive bladder cancer ($124.52, -0.55)

• 10:25 AM ET Jul 10, 2026
  

  FDA approves Keytruda and Keytruda QLEX, each with Padcev, for muscle invasive bladder cancer ($124.52, -0.55)

• 08:24 AM ET Jul 09, 2026
  

  Astellas to spotlight new research for Geographic Atrophy at ASRS 2026 Annual Meeting (¥2137.5000, 0)

• 09:50 AM ET Jun 29, 2026
  

  StreetAccount Summary - Private company transactions for the week ended 27-Jun

• 09:03 AM ET Jun 29, 2026
  

  PADCEV approved in Canada for patients with Muscle-Invasive Bladder Cancer unable to receive Cisplatin-based therapy ($24.29, 0.00)

• 06:48 AM ET Jun 24, 2026
  

  European Commission approves Merck's KEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) as first PD-1 inhibitor plus antibody-drug conjugate regimen for adults with Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer ($119.60, 0.00)

• 08:10 AM ET Jun 23, 2026
  

  Sangamo Therapeutics enters into asset sale agreements with Lilly and Astellas; commences voluntary Chapter 11 proceedings ($0.17, 0.00)

• 01:02 AM ET Jun 05, 2026
  

  UCB announces new EULAR 2026 data show CIMZIA (certolizumab pegol) delivered consistent effect in rheumatoid arthritis, regardless of rheumatoid factor (RF) levels (€259.50, 0.00)

• 08:55 AM ET Jun 03, 2026
  

  Transcript Intelligence: Astellas Pharma at Jefferies Global Healthcare Conference

• 09:43 AM ET May 30, 2026
  

  Pfizer announces TALZENNA plus XTANDI improves radiographic progression-free survival by more than 50% in metastatic prostate cancer ($26.18, 0.00)